Literature DB >> 23773141

Cluster headache: conventional pharmacological management.

Werner J Becker1.   

Abstract

Cluster headache pain is very intense, usually increases in intensity very rapidly from onset, and attacks are often frequent. These clinical features result in significant therapeutic challenges. The most effective pharmacological treatment options for acute cluster attack include subcutaneous sumatriptan, 100% oxygen, and intranasal zolmitriptan. Subcutaneous or intramuscular dihydroergotamine and intranasal sumatriptan are additional options. Transitional therapy is applicable mainly for patients with high-frequency (>2 attacks per day) episodic cluster headache, and options include short courses of high-dose oral corticosteroids, dihydroergotamine, and occipital nerve blocks with local anesthetic and steroids. Prophylactic therapy is important both for episodic and chronic cluster headache, and the main options are verapamil and lithium. Verapamil is drug of first choice but may cause cardiac arrhythmias, and periodic electrocardiograms (EKGs) during dose escalation are important. Many other drugs are also in current use, but there is an insufficient evidence base to recommend them.
© 2013 American Headache Society.

Entities:  

Keywords:  cluster headache; prophylactic medication; transitional medications

Mesh:

Substances:

Year:  2013        PMID: 23773141     DOI: 10.1111/head.12145

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  11 in total

Review 1.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 2.  Cluster headache pathophysiology - insights from current and emerging treatments.

Authors:  Diana Y Wei; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2021-03-29       Impact factor: 42.937

3.  High-Dose Verapamil in Episodic and Chronic Cluster Headaches and Cardiac Adverse Events: Is It as Safe as We Think?

Authors:  Joachim Alexandre; Xavier Humbert; Marion Sassier; Paul Milliez; Antoine Coquerel; Sophie Fedrizzi
Journal:  Drug Saf Case Rep       Date:  2015-12

4.  Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study.

Authors:  Stephen D Silberstein; Laszlo L Mechtler; David B Kudrow; Anne H Calhoun; Candace McClure; Joel R Saper; Eric J Liebler; Emily Rubenstein Engel; Stewart J Tepper
Journal:  Headache       Date:  2016-09       Impact factor: 5.887

5.  Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study.

Authors:  Charly Gaul; Delphine Magis; Eric Liebler; Andreas Straube
Journal:  J Headache Pain       Date:  2017-02-14       Impact factor: 7.277

Review 6.  P-glycoprotein and chronic rhinosinusitis.

Authors:  Marcel M Miyake; Angela Nocera; Michelle M Miyake
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2018-08-24

7.  Managing cluster headache.

Authors:  Diana Y Wei; Modar Khalil; Peter J Goadsby
Journal:  Pract Neurol       Date:  2019-07-05

8.  Propofol and alfentanil in treatment of a patient with episodic cluster headache.

Authors:  Sajjad Razavi; Babak Gharaei; Alireza Jafari; Homayoun Aghamohammadi; Alireza Mirkheshti
Journal:  Anesth Pain Med       Date:  2014-05-03

Review 9.  The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias.

Authors:  Alfredo Costa; Fabio Antonaci; Matteo Cotta Ramusino; Giuseppe Nappi
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

10.  COVID-19 and Headache Medicine: A Narrative Review of Non-Steroidal Anti-Inflammatory Drug (NSAID) and Corticosteroid Use.

Authors:  Karissa N Arca; Jonathan H Smith; Chia-Chun Chiang; Amaal J Starling; Carrie E Robertson; Rashmi B Halker Singh; Todd J Schwedt; Narayan R Kissoon; Ivan Garza; Todd D Rozen; Christoper J Boes; Mark A Whealy; Juliana H VanderPluym
Journal:  Headache       Date:  2020-07-10       Impact factor: 5.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.